Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579087 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577356 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL3959220 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577464 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577430 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL6577467 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL8357720 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL8357002 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL98284 | 1.00 | SIGMAR1 (0.57) | SIGMAR1MAPTRXFP1MAOAMAOB | |
| SCHEMBL96648 | 0.98 | SIGMAR1 (0.54) | SIGMAR1MAPTRXFP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| CN-108401825-A | A kind of galangal inoculation method rich in various trace elements | 佛山市三水区嘉信农业技术研究院（普通合伙） | 2018-08-17 | — | — | CN | disclosed |
| CN-108066683-A | Application of the galangal in the drug or health products for preparing the gastric ulcer that prevention and treatment non-steroidal anti-inflammatory drugs triggers | 海南医学院 | 2018-05-25 | — | — | CN | disclosed |
| CN-105054066-B | A kind of galangal rhizome extract and its preparation method and application | 中国热带农业科学院农产品加工研究所 | 2018-05-01 | — | — | CN | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| CN-105969329-A | Low-permeability reservoir artificial crack high-permeability-grading low-fingering residue-free acidizing fluid and preparation method thereof | 宁夏朔光石油科技有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| WO-2000012492-A1 | BENZOXAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| US-5998635-A | CATALYTIC CYCLIZATION AN ALDEHYDE WITH A KETENE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0856007-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GmbH (DE) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997014716-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-04-24 | — | — | WO | disclosed |
| EP-0338887-B1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMA (US) | 1993-12-08 | — | — | EP | disclosed |
| US-4988680-A | Phosphorylase inhibitors, immuno suppressants, parasiticides, antileukemia agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0338168-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338887-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| CN-85108623-A | Preparation has the novel method of the heterocycleamide of medical active | — | 1986-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | SIGMAR1 4091/4885MAPT 2196/4885RXFP1 2555/4885 |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | SIGMAR1 2226/4885MAPT 4254/4885RXFP1 175/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | SIGMAR1 4091/4885MAPT 2196/4885RXFP1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.